Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Tags › Posts tagged Pharmaceutical Industry

Tag: Pharmaceutical Industry

An exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London, Friday, May 2, 2014.  The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion. (AP Photo/Matt Dunham) Business

AstraZeneca rejects sweetened Pfizer takeover bid

DANICA KIRKALINDA A. JOHNSON · May 2, 2014 9:34 pm
AstraZeneca board rejects sweetened takeover offer from Pfizer Business

AstraZeneca board rejects sweetened takeover offer from Pfizer

Washington Examiner · May 2, 2014 9:56 am
West-Ward Pharmaceuticals settles with Texas, feds for $10M

West-Ward Pharmaceuticals settles with Texas, feds for $10M

Bryan Cohen · May 1, 2014 7:22 pm
Pfizer still pursuing AstraZeneca after 2nd rebuff Business

Pfizer still pursuing AstraZeneca after 2nd rebuff

DANICA KIRKALINDA A. JOHNSON · April 28, 2014 6:59 pm
AstraZeneca shares soar on Pfizer interest Business

AstraZeneca shares soar on Pfizer interest

Danica Kirka · April 28, 2014 11:16 am
FDA reviews psychiatric side effects of Chantix Business

FDA reviews psychiatric side effects of Chantix

Matthew Perrone · April 25, 2014 9:35 pm
Prestige to buy Insight Pharma for about $750M Business

Prestige to buy Insight Pharma for about $750M

Washington Examiner · April 25, 2014 12:01 pm
(Illustration by Karen Lomax/Examiner) Economy

Big Ideas: On Big Tech, expensive drugs and haunted islands

Joseph Lawler · April 25, 2014 4:00 am
Pfizer to help investors with dividend, buybacks Business

Pfizer to help investors with dividend, buybacks

The Associated Press · April 24, 2014 9:08 pm
J&J: Business doing well on new product approvals Business

J&J: Business doing well on new product approvals

Linda Johnson · April 24, 2014 8:27 pm
FILE - The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.  (AP Photo/Keystone, Steffen Schmidt) Business

New drug sales help boost Novartis Q1 profit

John Heilprin · April 24, 2014 4:46 pm
When things go well, the Food and Drug Administration typically hears little praise from Congress and the media. (Thinkstock) Healthcare

Manhattan Moment: Seeking best practices at the FDA

Paul Howard · April 24, 2014 4:00 am
Advertisement
  • ‹Previous page
  • 1
  • …
  • 135
  • 136
  • 137
  • 138
  • 139
  • …
  • 142
  • ›Next page
Page 137 of 142
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement